QNCX Quince Therapeutics, Inc. - 10-K
Filed Apr 10, 2026 for fiscal period ending Dec 31, 2025. See issuer overview · financials · original on SEC.gov ↗
Accession
0001193125-26-151364Signal
Neutralfull-docYoY shift: Unscored
Year-over-year tone shift - average net-tone change across Risk Factors and MD&A vs the prior 10-K.
Why YoY instead of absolute: the LM lexicon has ~6.6× more negative words than positive (legal/risk-disclosure language is heavy on hedging), so every 10-K reads bearish on raw tone. Year-over-year change strips that bias and surfaces the actual shift in management's framing.
Per-snippet highlights
Sentence-level sentiment highlighting with category and subcategory filters is coming once the snippet-scoring pipeline lands. For now, dig into the actual section text on the Sections tab.
No section text extracted for this filing. The 10-K may use a non-standard template that the parser doesn't recognize - the original doc is still linked in the Stats tab.
No section text extracted for this filing. The 10-K may use a non-standard template that the parser doesn't recognize - the original doc is still linked in the Stats tab.
Material contracts, certifications & more
7 exhibits filed with this 10-K
- Exhibit 3.4qncx-ex3_4.htm · 13.7 KB
- Exhibit 23.1: Consent of Independent Auditorsqncx-ex23_1.htm · 3.9 KB
- Exhibit 31.1: Rule 13a-14(a) Certification (CEO)qncx-ex31_1.htm · 15.1 KB
- Exhibit 31.2: Rule 13a-14(a) Certification (CFO)qncx-ex31_2.htm · 14.4 KB
- Exhibit 32.1: Section 1350 Certification (CEO)qncx-ex32_1.htm · 12.5 KB
- Exhibit 32.2: Section 1350 Certification (CFO)qncx-ex32_2.htm · 12.1 KB
- 0001193125-26-151364-index-headers.html0001193125-26-151364-index-headers.html
- Ticker
- QNCX
- CIK
0001662774- Form Type
- 10-K
- Accession Number
0001193125-26-151364- Filed
- Apr 10, 2026
- Period
- Dec 31, 2025 (Q4 25)
- Industry
- Biological Products, (No Diagnostic Substances)
External resources
Permalink
https://insiderdelta.com/issuers/QNCX/10-k/0001193125-26-151364